Cytokinetics(US:CYTK) ZACKS·2025-10-29 15:10Core Viewpoint - The market anticipates Cytokinetics (CYTK) will report a year-over-year decline in earnings despite a significant increase in revenues when it releases its quarterly results for the period ending September 2025 [1][3]. Earnings Expectations - Cytokinetics is expected to report a quarterly loss of $1.59 per share, reflecting a year-over-year change of -16.9% [3]. - Revenue is projected to be $5.56 million, which represents a substantial increase of 1108.7% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.21% higher in the last 30 days, indicating a slight positive adjustment by analysts [4]. - The Most Accurate Estimate for Cytokinetics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.53%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a focus on positive readings for predictive power [9][10]. - Cytokinetics currently holds a Zacks Rank of 3 (Hold), complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Cytokinetics was expected to post a loss of $1.34 per share but actually reported a loss of -$1.12, resulting in a positive surprise of +16.42% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates two times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Qiagen (QGEN) is expected to report earnings of $0.58 per share for the same quarter, indicating a year-over-year change of -1.7% [18]. - Qiagen's revenue is projected to be $525.99 million, up 4.8% from the previous year, with a consensus EPS estimate revised 0.7% lower recently [19].